BioCentury | Mar 19, 2021
Deals

March 18 Quick Takes: SPAC Revolution, Idera, Translate tumble; plus Anima-Takeda, Boston-GSK, Accelmed, Gain IPO and more

$500M IPO for SPAC backed by Arch, General Catalyst, LeidenBlank-check company Revolution Healthcare Acquisition Corp. (NASDAQ:REVHU) raised $500 million in an initial public offering through the sale of 50 million units at $10, with each...
BioCentury | Jan 9, 2021
Finance

4Q20 Wrap: Stocking up

...valuations below $25 million were excluded from the analysis. At the head of the pack was Curis Inc....
...remestemcel-L) ARV-471 ARV-110 eprenetapopt (APR-246, prima-1met) AU-4948, CA-4948 Multimeric-001 Universal Flu Vaccine (M-001, bvx-m001) Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) JD Health International Inc. Curis Inc. Johnson...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...Linimeier is anticipating updated Phase I data from Curis Inc....
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

...most companies are pursuing the target in inflammatory and immune indications, some are focusing on cancer.Curis Inc....
...finger 1 (IKAROS) (IKZF1) (LYF1)IRAK4 – Interleukin-1 receptor-associated kinase 4 Danielle Golovin PF-06650808 R835 Pfizer Inc. Rigel Pharmaceuticals Inc. Kymera Therapeutics Inc. Curis Inc. Interleukin-1...
BioCentury | Dec 9, 2020
Product Development

Dec. 8 Quick Takes: Amgen’s KRAS inhibitor nears FDA submission; plus Curis, BeiGene, Pfizer, Forma, Agios, Lyra, Bellicum, Illumina-Harvard Pilgrim

...designation and accepted it into its real-time cancer review pilot.ASH data propel Curis sharesShares of Curis Inc....
...MEDI-538) sotorasib (AMG 510) Amgen Inc. BeiGene Ltd. Harvard Pilgrim Health Care Inc. Pfizer Inc. Lyra Therapeutics Inc. Agios Pharmaceuticals Inc. Bellicum Pharmaceuticals Inc. Curis Inc. Forma...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...VISTA is the small molecule inhibitor CA-170 (CA-170) from Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) and Curis Inc....
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...is stepping down for personal reasons. Lieber was CFO at Histogenics Corp. (NASDAQ:HSGX). Cancer company Curis Inc....
...Editor and Hongjiang Li, Staff Writer CASI Pharmaceuticals Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo Pharma S.A. Curis Inc. X4...
BioCentury | Jul 3, 2019
Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

Shiyu Capital leads Lepu’s $131M A round Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing...
BioCentury | Jun 25, 2019
Distillery Therapeutics

Herb-derived flavonoid identified as potential TNBC treatment

...include Erivedge vismodegib from the Genentech Inc. unit of Roche, Chugai Pharmaceutical Co. Ltd. and Curis Inc....
Items per page:
1 - 10 of 502
BioCentury | Mar 19, 2021
Deals

March 18 Quick Takes: SPAC Revolution, Idera, Translate tumble; plus Anima-Takeda, Boston-GSK, Accelmed, Gain IPO and more

$500M IPO for SPAC backed by Arch, General Catalyst, LeidenBlank-check company Revolution Healthcare Acquisition Corp. (NASDAQ:REVHU) raised $500 million in an initial public offering through the sale of 50 million units at $10, with each...
BioCentury | Jan 9, 2021
Finance

4Q20 Wrap: Stocking up

...valuations below $25 million were excluded from the analysis. At the head of the pack was Curis Inc....
...remestemcel-L) ARV-471 ARV-110 eprenetapopt (APR-246, prima-1met) AU-4948, CA-4948 Multimeric-001 Universal Flu Vaccine (M-001, bvx-m001) Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) JD Health International Inc. Curis Inc. Johnson...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...Linimeier is anticipating updated Phase I data from Curis Inc....
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

...most companies are pursuing the target in inflammatory and immune indications, some are focusing on cancer.Curis Inc....
...finger 1 (IKAROS) (IKZF1) (LYF1)IRAK4 – Interleukin-1 receptor-associated kinase 4 Danielle Golovin PF-06650808 R835 Pfizer Inc. Rigel Pharmaceuticals Inc. Kymera Therapeutics Inc. Curis Inc. Interleukin-1...
BioCentury | Dec 9, 2020
Product Development

Dec. 8 Quick Takes: Amgen’s KRAS inhibitor nears FDA submission; plus Curis, BeiGene, Pfizer, Forma, Agios, Lyra, Bellicum, Illumina-Harvard Pilgrim

...designation and accepted it into its real-time cancer review pilot.ASH data propel Curis sharesShares of Curis Inc....
...MEDI-538) sotorasib (AMG 510) Amgen Inc. BeiGene Ltd. Harvard Pilgrim Health Care Inc. Pfizer Inc. Lyra Therapeutics Inc. Agios Pharmaceuticals Inc. Bellicum Pharmaceuticals Inc. Curis Inc. Forma...
BioCentury | Jan 24, 2020
Preclinical News

Jan. 23 Preclinical Quick Takes: Metastasis-associated cancer-associated fibroblast populations; plus NIH-TeneoBio and Basilea

Cancer-associated fibroblast subsets linked to metastasis In a study published in Nature Communications , a team from Institut Curie and INSERM identified within breast cancer patients’ lymph nodes four subpopulations of cancer-associated fibroblasts (CAFs). Two subsets...
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

...VISTA is the small molecule inhibitor CA-170 (CA-170) from Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) and Curis Inc....
BioCentury | Sep 19, 2019
Company News

Management tracks: CASI promotes Zhang to president; plus Five Prime, Black Diamond, Oyster Point, Enyo, X4, Nimbus and Canbridge

...is stepping down for personal reasons. Lieber was CFO at Histogenics Corp. (NASDAQ:HSGX). Cancer company Curis Inc....
...Editor and Hongjiang Li, Staff Writer CASI Pharmaceuticals Inc. Black Diamond Therapeutics Inc. Oyster Point Pharma Inc. Enyo Pharma S.A. Curis Inc. X4...
BioCentury | Jul 3, 2019
Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

Shiyu Capital leads Lepu’s $131M A round Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing...
BioCentury | Jun 25, 2019
Distillery Therapeutics

Herb-derived flavonoid identified as potential TNBC treatment

...include Erivedge vismodegib from the Genentech Inc. unit of Roche, Chugai Pharmaceutical Co. Ltd. and Curis Inc....
Items per page:
1 - 10 of 502